As more patients with cancer have their tumors genomically profiled, and more therapies targeting genomic alterations enter clinical trials, the task of connecting patients to trials for which they are eligible can be especially ...
Oct 12, 2022
0
35
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer ...
Sep 8, 2022
0
11
With research suggesting that many patients with cancer are using cannabis for medical purposes—and oncology teams tending to offer little guidance about its use—patients are often turning for advice to staff at cannabis ...
Aug 15, 2022
0
19
An online tool developed by researchers and physicians at Dana-Farber Cancer Institute can accurately and rapidly identify people who should undergo testing for inherited genetic changes that raise the risk of developing ...
Aug 15, 2022
0
12
Sexual dysfunction is highly prevalent in women with lung cancer with most survey participants reporting little to no interest in sexual activity, according to research led by Narjust Florez (Duma), MD, associate director ...
Aug 9, 2022
0
2
The treatment of breast cancer abounding in the protein HER2 was revolutionized with the introduction of drugs like trastuzumab (Herceptin) that target the protein. When researchers discovered that breast cancers with lower ...
Jun 24, 2022
0
8
Results of a study of molecular tumor profiling in young patients revealed a high rate of genetic alterations with potential for impacting clinical care, including clarifying diagnoses and treatment with matched, precision ...
Jun 23, 2022
0
49
For many years, the human genome was viewed as a book of life in which sections of great eloquence and economy of expression were interspersed with vast stretches of gibberish. The legible sections contained the code for ...
Jun 13, 2022
0
60
Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute ...
Jun 5, 2022
0
108
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions ...
Jun 3, 2022
0
2
